Friday , 21 June 2024

Formulation and In-Vitro Evaluation of Selegiline Buccal Patches

Samhitha M1, Ramesh K2, Dr. Gampa Vijay kumar3, Kishore K4
Department of Pharmaceutics, KGR Institute of Technology and Management, Rampally, Keesara, Rangareddy, Telangana, India

Selegiline, also known as L-deprenyl, is a medication which is used in the treatment of Parkinson’s disease and major depressive disorder. It is provided in the form of a capsule or tablet taken by mouth for Parkinson’s disease and as a patch applied to skin for depression. In present study buccal drug delivery of Selegiline was developed to overcome the first pass metabolism and to reduce frequency of dosing compared to oral route.  Matrix type of buccal patches was developed by using polymers Methocel K15M, Sodium CMC, Chitosan. Buccal patches were prepared by employing solvent casting method. Propylene glycol and Tween80 were selected as permeation enhancer and plasticizer.  Drug excipient compatibility studies were carried out by using FTIR, and it was observed that there were no interactions. Formulations were prepared with the varying concentrations polymers ranging from F1-F9, and all the formulations were evaluated for various physical parameters Physical appearance, Flatness, Weight variation, Thickness, Folding endurance, Drug content, Moisture uptake and Moisture content and all the results were found to be were found to be with in the pharmacopeial limits, in-vitro drug release studies by using dialysis membrane. Among all the 12 formulations F6 formulation which contain Sodium CMC 100mg  had shown 98.53% cumulative drug release with in 12 hours. And compared to Methocel K15M, Chitosan showed better drug release profile.
Keywords: Selegiline, Methocel K15M, Sodium CMC, Chitosan Transdermal patches

Scroll To Top